Ibandroninezuur Synthon (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to hydroxyapatite on bone surfaces undergoing active remodeling. When osteoclasts attach to this drug‑coated bone, the compound is taken up and interferes with the mevalonate pathway, leading to osteoclast apoptosis and a consequent reduction in bone resorption.

The specific dose and infusion schedule are determined by the prescribing clinician based on the patient’s indication, renal function and overall health. Healthcare professionals should follow the product’s prescribing information and adjust the regimen as needed.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ibandroninezuur Synthon is administered intravenously, offering a convenient dosing interval (often once every three months) compared with oral bisphosphonates that require weekly or monthly dosing. Its potency in inhibiting bone resorption is comparable to other IV agents such as zoledronic acid, but the safety profile and infusion schedule may differ, influencing clinician choice.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperature fluctuations to maintain stability until the time of use.

Ibandroninezuur Synthon is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically performed over a short period (e.g., 15 minutes) under medical supervision, with monitoring for any acute reactions during and after the administration.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, marked hypocalcaemia and anaphylactic reactions. Patients should be educated about these risks, and clinicians should monitor renal function, calcium levels and oral health before and during therapy.

Ibandroninezuur Synthon is contraindicated in patients with known hypersensitivity to ibandronic acid or any excipients, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with existing hypocalcaemia that has not been corrected. Caution is also advised for patients with active dental infections or recent oral surgery.